Kiniksa Pharmaceuticals (KNSA) to Release Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The business had revenue of $108.30 million for the quarter, compared to analysts' expectations of $90.60 million. During the same quarter last year, the company earned ($0.02) EPS. The business's revenue was up 51.5% on a year-over-year basis. On average, analysts expect Kiniksa Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock traded up $0.05 during trading on Wednesday, reaching $26.84. The company had a trading volume of 223,055 shares, compared to its average volume of 412,151. The firm's 50-day simple moving average is $25.61 and its 200 day simple moving average is $22.11. Kiniksa Pharmaceuticals has a 1-year low of $14.12 and a 1-year high of $27.92. The firm has a market capitalization of $1.90 billion, a PE ratio of 243.55 and a beta of 0.33.

Insider Activity at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares of the company's stock, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 17,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,692 shares of company stock worth $2,950,315. Company insiders own 54.57% of the company's stock.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.